Costimulation Induces CD4 T Cell Antitumor Immunity via an Innate-like Mechanism

Abstract

Summary: Chronic exposure to tumor-associated antigens inactivates cognate T cells, restricting the repertoire of tumor-specific effector T cells. This problem was studied here by transferring TCR transgenic CD4 T cells into recipient mice that constitutively express a cognate self-antigen linked to MHC II on CD11c-bearing cells. Immunotherapeutic agonists to CD134 plus CD137, “dual costimulation,” induces specific CD4 T cell expansion and expression of the receptor for the Th2-associated IL-1 family cytokine IL-33. Rather than producing IL-4, however, they express the tumoricidal Th1 cytokine IFNγ when stimulated with IL-33 or IL-36 (a related IL-1 family member) plus IL-12 or IL-2. IL-36, which is induced within B16-F10 melanomas by dual costimulation, reduces tumor growth when injected intratumorally as a monotherapy and boosts the efficacy of tumor-nonspecific dual costimulated CD4 T cells. Dual costimulation thus enables chronic antigen-exposed CD4 T cells, regardless of tumor specificity, to elaborate tumoricidal function in response to tumor-associated cytokines. : Morales Del Valle et al. analyze how immunotherapeutic costimulatory agonists specific to CD134 and CD137 overcome peripheral tolerance mechanisms that restrict effector T cell programming. Costimulation enables CD4 helper T cells to secrete the tumoricidal cytokine IFNγ via an innate-like TCR-independent process that involves stimulation with IL-1 family cytokines.